Abstract
Coronavirus disease-2019 (COVID-19) is a respiratory tract infection accompanied by severe or fatal pneumonia-like symptoms and sometimes death. It has posed to be an ongoing global health emergency caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Due to a sudden outbreak and a large number of infections and deaths, it became a major concern all over the world. The options available as effective therapeutics should be urgently exercised to handle this pandemic. So far, no specific and accurate anti- SARS-CoV-2 treatment is recommended because of the absence of sufficient clinical evidence. In such cases, the clinical use of available drugs is always considered to be on top priority. A broad-spectrum antiviral agent, remdesivir, is found effective in many cases and recommended by many clinicians in many countries. This drug acts as a potential inhibitor of viral RNA-dependent RNA polymerase protein and thus likely to be efficacious in SARS-CoV-2 infection. Tocilizumab is currently recommended by many hospitals as an alternative treatment for critically ill COVID-19 patients. Tocilizumab has been administered to control cytokine storms that occur due to the release of proinflammatory cytokine, including interleukin 6. Chloroquine and hydroxychloroquine are also used in hospitals to handle severe COVID-19 patients. Currently, plasma therapy has been exercised as a therapeutic alternative, especially to handle severe COVID-19 patients. In addition, herbal medicines are expected to play a significant role in the control and prevention of COVID-19. All these therapeutic options have their advantages and limitations. This review highlights the therapeutic potential of these available drugs, along with their mechanism of action and shortcomings. We have provided detailed information on available therapeutic options, which have proved to be effective in improving clinical symptoms of severe COVID-19 patients.
Keywords: SARS‐CoV‐2, COVID‐19, remdesivir, Chinese herbal medicine, tocilizumab, hydroxychloroquine, chloroquine, plasma therapy, cytokine storm.
Current Pharmaceutical Design
Title:Therapeutic Management of COVID-19 Patients: Clinical Manifestation and Limitations
Volume: 27 Issue: 41
Author(s): Urooj Fatima, Syed Saif A. Rizvi, Neha Raina, Saher Fatima, Safikur Rahman, Md. Amjad Kamal and Md. Imtaiyaz Hassan*
Affiliation:
- Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar New Delhi 110025,India
Keywords: SARS‐CoV‐2, COVID‐19, remdesivir, Chinese herbal medicine, tocilizumab, hydroxychloroquine, chloroquine, plasma therapy, cytokine storm.
Abstract: Coronavirus disease-2019 (COVID-19) is a respiratory tract infection accompanied by severe or fatal pneumonia-like symptoms and sometimes death. It has posed to be an ongoing global health emergency caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Due to a sudden outbreak and a large number of infections and deaths, it became a major concern all over the world. The options available as effective therapeutics should be urgently exercised to handle this pandemic. So far, no specific and accurate anti- SARS-CoV-2 treatment is recommended because of the absence of sufficient clinical evidence. In such cases, the clinical use of available drugs is always considered to be on top priority. A broad-spectrum antiviral agent, remdesivir, is found effective in many cases and recommended by many clinicians in many countries. This drug acts as a potential inhibitor of viral RNA-dependent RNA polymerase protein and thus likely to be efficacious in SARS-CoV-2 infection. Tocilizumab is currently recommended by many hospitals as an alternative treatment for critically ill COVID-19 patients. Tocilizumab has been administered to control cytokine storms that occur due to the release of proinflammatory cytokine, including interleukin 6. Chloroquine and hydroxychloroquine are also used in hospitals to handle severe COVID-19 patients. Currently, plasma therapy has been exercised as a therapeutic alternative, especially to handle severe COVID-19 patients. In addition, herbal medicines are expected to play a significant role in the control and prevention of COVID-19. All these therapeutic options have their advantages and limitations. This review highlights the therapeutic potential of these available drugs, along with their mechanism of action and shortcomings. We have provided detailed information on available therapeutic options, which have proved to be effective in improving clinical symptoms of severe COVID-19 patients.
Export Options
About this article
Cite this article as:
Fatima Urooj , Rizvi Saif A. Syed , Raina Neha , Fatima Saher, Rahman Safikur, Kamal Amjad Md. and Hassan Imtaiyaz Md. *, Therapeutic Management of COVID-19 Patients: Clinical Manifestation and Limitations, Current Pharmaceutical Design 2021; 27 (41) . https://dx.doi.org/10.2174/1381612826666201125112719
DOI https://dx.doi.org/10.2174/1381612826666201125112719 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Fibrate Treatment in Dyslipidemia: An Overview
Current Pharmaceutical Design Alzheimer Disease and Diabetes Mellitus: Do They have Anything in Common?
Current Alzheimer Research PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Circadian Rhythm in Cytokines Administration
Mini-Reviews in Medicinal Chemistry The Mast Cell: A Potential Therapeutic Target in Myocardial Infarction
Drug Design Reviews - Online (Discontinued) An Overview of Piperazine Scaffold as Promising Nucleus for Different Therapeutic Targets
Current Pharmaceutical Design Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice
Current Cardiology Reviews Respiratory Syncytial Virus (RSV) Prevention and Treatment: Past, Present, and Future
Cardiovascular & Hematological Agents in Medicinal Chemistry Mitochondrial, Metabolic and Genotoxic Effects of Antiretroviral Nucleoside Reverse-Transcriptase Inhibitors
Anti-Infective Agents in Medicinal Chemistry Pharmacological Considerations during Percutaneous Treatment of Heart Failure
Current Pharmaceutical Design N-Stearoylethanolamine Exerts Cardioprotective Effects in Old Rats
Current Aging Science The Medicinal Chemistry of Genus <i>Aralia</i>
Current Topics in Medicinal Chemistry MicroRNAs as Potential Biomarkers in Coronary Artery Disease
Current Topics in Medicinal Chemistry Recent Advances in Liposomal Drug Delivery: A Review
Pharmaceutical Nanotechnology Methods to Evaluate the Inhibition of TTR Fibrillogenesis Induced by Small Ligands
Current Medicinal Chemistry Matrix Metalloproteinase Inhibitors as Prospective Agents for the Prevention and Treatment of Cardiovascular and Neoplastic Diseases
Current Topics in Medicinal Chemistry Editorial: (New Drug (LCZ696) for the Treatment of Heart Failure with Reduced Ejection Fraction After 10 Years. Can One Study Change the Guidelines?)
Current Vascular Pharmacology MDMA Toxicity and Pathological Consequences: A Review About Experimental Data and Autopsy Findings
Current Pharmaceutical Biotechnology Mitochondrial Dysfunction and Its Relationship with mTOR Signaling and Oxidative Damage in Autism Spectrum Disorders
Mini-Reviews in Medicinal Chemistry Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and Research
Current Pharmaceutical Design